secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2026-11-10T22:15:38+00:00
Accession:  0001213900-26-118109
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

CorMedix to acquire substantially all Heron Therapeutics assets, adding four FDA-approved brands including ZYNRELEF
--------------------------------------------------------------------------------

- CorMedix entered a definitive asset purchase agreement to buy substantially all of Heron Therapeutics' assets; deal announced November 9, 2026, with a Pharmakon term loan facility involved in funding.
- Consideration includes CorMedix common stock issued to Heron in a private placement; Heron stockholders must vote on the transaction; earn-out milestones and royalty payments are contemplated.
- Acquired portfolio is described as four FDA-approved commercial brands, including ZYNRELEF, expected to diversify revenue and be accretive to earnings.
- Closing conditioned on Heron stockholder approval and required regulatory clearances; the agreement includes a termination fee payable by Heron in specified circumstances.
- No purchase price, per-share value or premium is disclosed in the filed text; continued separate payment for ZYNRELEF under the NOPAIN Act is cited as a revenue driver.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026118109/0001213900-26-118109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026118109/ea0311532-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-118109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer